Yahoo Finance AstraZeneca Gets a Boost from U.S. Travel Rules Tweak, Breast Cancer Drug Trial
By Dhirendra Tripathi
Investing.com – AstraZeneca ADRs (NASDAQ:AZN) traded 1% higher in Tuesday’s premarket as the proposed changes to rules governing travel to the U.S. will accommodate those vaccinated by the company’s Covid-19 shots.
The Oxford-AstraZeneca vaccine is still not approved by the U.S. drugs regulator. But according to comments made by Anthony Fauci, a top infectious diseases expert who heads the U.S. response to the pandemic, it looks like those vaccinated by the vaccine will face no problem entering the U.S.
“Given we have a substantial amount of information on the AZ vaccine . . . I would predict it would not be a problem,” he said, according to The Times of London.
The U.S. eased travel rules Monday, allowing fully vaccinated travelers to enter the country from November onward without them having to quarantine. They will have to present a proof of vaccination before boarding and proof of a negative Covid-19 test taken within three days of the flight.
The easing of travel rules and Fauci’s comments added to the positive sentiment for the stock generated by the findings of a study involving the company’s potential drug to treat breast cancer. The company on Saturday said Enhertu, an antibody drug conjugate, demonstrated superior outcomes compared to the existing treatment. The company is jointly developing the drug with Japan’s Daiichi Sankyo (T:4568).
Related Articles
AstraZeneca Gets a Boost from U.S. Travel Rules Tweak, Breast Cancer Drug Trial
Spanish housing stock drops after lockdown-driven buying spree
Japan's MUFG pulls back from U.S. retail banking in $8 billion deal with U.S. Bancorp
